J 2018

Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors

MINÁŘ, Luboš, Michal FELSINGER, Zdeňka ČERMÁKOVÁ, Filip ZLÁMAL, Julie BIENERTOVÁ VAŠKŮ et. al.

Basic information

Original name

Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors

Authors

MINÁŘ, Luboš (203 Czech Republic, guarantor, belonging to the institution), Michal FELSINGER (203 Czech Republic, belonging to the institution), Zdeňka ČERMÁKOVÁ (203 Czech Republic), Filip ZLÁMAL (203 Czech Republic, belonging to the institution) and Julie BIENERTOVÁ VAŠKŮ (203 Czech Republic, belonging to the institution)

Edition

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, CLARE, ELSEVIER IRELAND LTD, 2018, 0020-7292

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30214 Obstetrics and gynaecology

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 1.671

RIV identification code

RIV/00216224:14110/18:00102797

Organization unit

Faculty of Medicine

DOI

UT WoS

000419300300018

Keywords in English

Cancer antigen 125; Copenhagen Index; Human epididymis protein 4; Ovarian tumor; Risk of Ovarian Malignancy Algorithm

Tags

Tags

International impact, Reviewed
Změněno: 26/3/2019 10:37, Soňa Böhmová

Abstract

V originále

Objective To compare the Copenhagen Index (CPH-I) and the Risk of Ovarian Malignancy Algorithm (ROMA) in the differential diagnosis of ovarian tumors. Methods In a retrospective study, data were reviewed from women with ovarian tumors who attended University Hospital Brno, Czech Republic, between July 2011 and June 2015. The women were classified into the benign tumor group or malignant tumor group (borderline and malignant tumors). Serum levels of CA125 and HE4 were extracted from medical records. The two tumor indices were calculated using relevant clinical data. Results Among 267 included women, 110 had benign tumors, 42 had borderline ovarian tumors, and 115 had malignant tumors. The two indices showed similar discriminatory performance with no significant differences (P>0.05). In the differentiation of benign tumors from all stages of borderline tumor and ovarian cancer, ROMA showed a sensitivity of 71% at a specificity of 88%, whereas CPH-I showed a sensitivity of 69% at a specificity of 85%. Conclusion CPH-I is a potential tumor index that is independent of menopausal status. It might be applied as a simple alternative to ROMA in settings of basic medical care.

Links

EF15_003/0000469, research and development project
Name: Cetocoen Plus
LM2015051, research and development project
Name: Centrum pro výzkum toxických látek v prostředí (Acronym: RECETOX RI)
Investor: Ministry of Education, Youth and Sports of the CR